LOX and neoplasm: Although ECM‐remodelling enzymes, including those in the LOX family, have been definitively linked to promoting tumour progression, invasion and metastasis, further elucidation of the correlation and mechanism between the LOX family and tumour drug resistance is imperative for their potential utilisation as therapeutic options in antitumor treatment.